

# James D Neaton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2387775/publications.pdf>

Version: 2024-02-01

52  
papers

7,740  
citations

304743

22  
h-index

197818

49  
g-index

57  
all docs

57  
docs citations

57  
times ranked

17779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <i>Clinical Trials</i> , 2022, 19, 52-61.	1.6	16
2	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
3	RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	5.0	17
4	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	7
5	What drives willingness to receive a new vaccine that prevents an emerging infectious disease? A discrete choice experiment among university students in Uganda. <i>PLoS ONE</i> , 2022, 17, e0268063.	2.5	7
6	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. <i>Aids</i> , 2021, 35, 193-204.	2.2	6
7	Partnership for Research on Ebola VACCination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. <i>Trials</i> , 2021, 22, 86.	1.6	9
8	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. <i>Aids</i> , 2021, 35, 783-789.	2.2	2
9	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. <i>American Journal of Hypertension</i> , 2020, 33, 43-52.	2.0	6
10	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	4.1	14
11	Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	27.0	5,834
12	Adult and paediatric haematology and clinical chemistry laboratory reference limits for Liberia. <i>African Journal of Laboratory Medicine</i> , 2020, 9, 1080.	0.6	2
13	The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. <i>Journal of Infectious Diseases</i> , 2019, 219, 254-263.	4.0	13
14	A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial. <i>Clinical Trials</i> , 2019, 16, 626-634.	1.6	11
15	Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25297.	3.0	26
16	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 951-963.	10.7	99
17	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1325-1334.	4.0	18
18	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	3.4	75

#	ARTICLE	IF	CITATIONS
19	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. <i>JAMA Cardiology</i> , 2019, 4, 515.	6.1	51
20	Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz137.	0.9	15
21	Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. <i>PLoS Medicine</i> , 2019, 16, e1002767.	8.4	20
22	A Longitudinal Study of Ebola Sequelae in Liberia. <i>New England Journal of Medicine</i> , 2019, 380, 924-934.	27.0	104
23	The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. <i>Aids</i> , 2019, 33, 1335-1344.	2.2	16
24	Serious Non-AIDS Conditions in HIV: Benefit of Early ART. <i>Current HIV/AIDS Reports</i> , 2018, 15, 162-171.	3.1	16
25	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV</i> , 2018, 5, e172-e180.	4.7	28
26	Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. <i>AIDS and Behavior</i> , 2018, 22, 2277-2283.	2.7	3
27	How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know. <i>Clinical Trials</i> , 2018, 15, 359-365.	1.6	17
28	Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 1-7.	2.1	49
29	Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx275.	0.9	18
30	1284. Study of Single Nucleotide Polymorphisms Associated with HIV-1 Set-Point Viral Load in Antiretroviral Therapy-Naïve HIV-Positive Participants of the START Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S392-S392.	0.9	0
31	A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias. <i>Nutrients</i> , 2018, 10, 884.	4.1	17
32	Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. <i>Clinical Trials</i> , 2017, 14, 264-276.	1.6	30
33	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	27.0	199
34	Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx212.	0.9	16
35	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0155100.	2.5	150
36	Letter by Kuller and Neaton Regarding Article, "Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans". <i>Circulation</i> , 2016, 133, e452.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	1.6	63
38	Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e95061.	2.5	67
39	Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. <i>Journal of the American Heart Association</i> , 2014, 3, e000844.	3.7	184
40	Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. <i>Journal of Electrocardiology</i> , 2014, 47, 264-271.	0.9	3
41	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014, 60, 295-300.	3.1	22
42	Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 480-490.	3.8	33
43	Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. <i>Clinical Trials</i> , 2010, 7, 705-718.	1.6	27
44	Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 112-117.	3.8	11
45	Key Issues in End Point Selection for Heart Failure Trials: Composite End Points. <i>Journal of Cardiac Failure</i> , 2005, 11, 567-575.	1.7	110
46	Pulse Pressure and Risk of Cardiovascular Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 175.	7.4	0
47	Pulse Pressure and Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 175.	7.4	0
48	Veterinary Randomized Clinical Trial Reporting: A Review of the Small Animal Literature. <i>Journal of Veterinary Internal Medicine</i> , 1998, 12, 57-60.	1.6	26
49	Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. <i>Cancer</i> , 1997, 79, 2171-2177.	4.1	61
50	Considerations in choice of a clinical endpoint for AIDS clinical trials. <i>Statistics in Medicine</i> , 1994, 13, 2107-2125.	1.6	85
51	Clinical Trial Design: Veterinary Perspectives. <i>Journal of Veterinary Internal Medicine</i> , 1994, 8, 317-322.	1.6	14
52	An examination of the efficiency of some quality assurance methods commonly employed in clinical trials. <i>Statistics in Medicine</i> , 1990, 9, 115-124.	1.6	61